KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.70

-0.42%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.90M
EPS-2.8500
P/E Ratio-1.65
Earnings Date08/12/2026

klrs

Total Non-Current Assets

Last Annual Value

2.93M

3-Year CAGR

%

5-Year CAGR

-21%

10-Year CAGR

-11%

KT

Kalaris Therapeutics Inc Competitors Analysis of Total Non-Current Assets

KLRS · NASDAQ
CompanyTotal Non-Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
2.93M
N/A-38.5%N/A 
60.49M
20.7%71.6%58.2%
18.27M
-10.3%19.1%N/A
8.55M
-19.4%-3.7%N/A
140.07K
108.2%22.7%N/A
55.56M
-13.7%10.9%N/A
48.54M
-2.9%-16.9%18.0%
8.32M
-46.4%-8.8%N/A
33.83M
-5.9%40.6%N/A
909.00K
-19.8%-51.7%N/A
97.59M
19.0%24.5%23.7%
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.7, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.7